113 related articles for article (PubMed ID: 37455427)
1. CD39 Expression in Peripheral T Cells is Associated with Clinicopathological Characteristics in Patients with Cervical Cancer.
Zhao K; Han D; Tang L; Jin H
Iran J Immunol; 2023 Sep; 20(3):276-286. PubMed ID: 37455427
[TBL] [Abstract][Full Text] [Related]
2. CD39 molecule: a negative regulator expressed on T cells in patients with lung adenocarcinoma.
Tang L; Jin H
Arch Med Sci; 2023; 19(5):1558-1563. PubMed ID: 37732039
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
[No Abstract] [Full Text] [Related]
5. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
6. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
7. [Artesunate upregulates the expression of CD39, CD279 and granzyme B in CD4
Xing Y; Gui S; Hu W; Su Y; Zhang W; Hu C; Liu Y; Xie J; Wu J; Hu D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):338-346. PubMed ID: 35583064
[TBL] [Abstract][Full Text] [Related]
8. Association between αβ and γδ T-cell subsets and clinicopathological characteristics in patients with breast cancer.
Zhang M; Lu X; Wei C; Li X
Oncol Lett; 2020 Dec; 20(6):325. PubMed ID: 33123241
[TBL] [Abstract][Full Text] [Related]
9. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
10. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
11. Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma.
Dong DN; Fan PW; Feng YN; Liu GH; Peng YC; Dong T; Wang RZ; Yu JM
Chin Med J (Engl); 2021 Aug; 134(17):2066-2072. PubMed ID: 34435978
[TBL] [Abstract][Full Text] [Related]
12. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
13. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
15. CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer.
Zhu W; Zhao Z; Feng B; Yu W; Li J; Guo H; Yang R
Onco Targets Ther; 2021; 14():2149-2161. PubMed ID: 33790578
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients.
Wu Y; Ye S; Goswami S; Pei X; Xiang L; Zhang X; Yang H
BMC Cancer; 2020 Mar; 20(1):173. PubMed ID: 32131750
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
19. An Altered Ratio of CD4+ And CD8+ T Lymphocytes in Cervical Cancer Tissues and Peripheral Blood – A Prognostic Clue?
Das D; Sarkar B; Mukhopadhyay S; Banerjee C; Biswas Mondal S
Asian Pac J Cancer Prev; 2018 Feb; 19(2):471-478. PubMed ID: 29480666
[TBL] [Abstract][Full Text] [Related]
20. Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression.
Wang YY; Zhou N; Liu HS; Gong XL; Zhu R; Li XY; Sun Z; Zong XH; Li NN; Meng CT; Bai CM; Li TS
Cancer Med; 2020 Jul; 9(14):5086-5094. PubMed ID: 32459060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
